Omnicell (OMCL) Earns Buy Rating from Cantor Fitzgerald
Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating restated by analysts at Cantor Fitzgerald in a research report issued on Tuesday. They currently have a $60.00 target price on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 17.65% from the company’s current price.
A number of other analysts have also recently issued reports on the company. Oppenheimer reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research report on Tuesday. Zacks Investment Research cut Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. Craig Hallum reissued a “buy” rating and set a $62.00 price target (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Finally, Benchmark lifted their price target on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $55.14.
Omnicell (NASDAQ OMCL) traded down $1.15 on Tuesday, hitting $51.00. The stock had a trading volume of 229,600 shares, compared to its average volume of 256,245. Omnicell has a 52 week low of $31.85 and a 52 week high of $55.40. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38.
In other Omnicell news, EVP Dan S. Johnston sold 14,613 shares of Omnicell stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.81, for a total value of $698,647.53. Following the completion of the transaction, the executive vice president now directly owns 43,621 shares of the company’s stock, valued at approximately $2,085,520.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robin Gene Seim sold 9,780 shares of Omnicell stock in a transaction on Friday, September 15th. The shares were sold at an average price of $48.97, for a total value of $478,926.60. Following the completion of the transaction, the executive vice president now directly owns 55,896 shares of the company’s stock, valued at $2,737,227.12. The disclosure for this sale can be found here. Insiders sold a total of 38,944 shares of company stock valued at $1,889,592 over the last ninety days. Insiders own 3.77% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Turner Investments LLC bought a new position in shares of Omnicell in the 2nd quarter valued at $181,000. Flinton Capital Management LLC increased its stake in shares of Omnicell by 74.6% in the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock valued at $182,000 after purchasing an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC increased its stake in shares of Omnicell by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after purchasing an additional 1,830 shares during the last quarter. Marco Investment Management LLC bought a new position in shares of Omnicell in the 3rd quarter valued at $231,000. Finally, Sei Investments Co. increased its stake in shares of Omnicell by 36.4% in the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock valued at $200,000 after purchasing an additional 1,242 shares during the last quarter. Institutional investors own 99.84% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Omnicell (OMCL) Earns Buy Rating from Cantor Fitzgerald” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/06/omnicell-omcl-earns-buy-rating-from-cantor-fitzgerald.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.